Literature DB >> 22188003

Vemurafenib for melanoma metastases to the brain.

Nicole M Rochet, Lisa A Kottschade, Svetomir N Markovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22188003     DOI： 10.1056/NEJMc1111672

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  32 in total

Review 1.  Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Authors:  Darshil J Shah; Roxana S Dronca
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 2.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

3.  Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.

Authors:  David A Liebner; Steven A Walston; Robert Cavaliere; Ciaran J Powers; Eric Sauvageau; Norman L Lehman; Hasel Wayne Slone; Meng Xu-Welliver; Fen Xia; Kari L Kendra
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

4.  A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Authors:  Lawrence Flaherty; Omid Hamid; Gerald Linette; Lynn Schuchter; Sigrun Hallmeyer; Rene Gonzalez; C Lance Cowey; Anna Pavlick; Fred Kudrik; Brendan Curti; David Lawson; Paul B Chapman; Kim Margolin; Antoni Ribas; David McDermott; Keith Flaherty; Lee Cranmer; F Stephen Hodi; Bann-Mo Day; Rolf Linke; John Hainsworth
Journal:  Cancer J       Date:  2014 Jan-Feb       Impact factor: 3.360

Review 5.  Targeted therapy in cancer.

Authors:  Apostolia-Maria Tsimberidou
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-21       Impact factor: 3.333

6.  Molecular subtyping of brain metastases and implications for therapy.

Authors:  Jaclyn J Renfrow; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2013-12

7.  Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).

Authors:  Rajendar K Mittapalli; Shruthi Vaidhyanathan; Ramola Sane; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2012-03-27       Impact factor: 4.030

8.  Melanoma brain metastases and vemurafenib: need for further investigation.

Authors:  Nicole M Rochet; Roxana S Dronca; Lisa A Kottschade; Rahul N Chavan; Brian Gorman; Julie R Gilbertson; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

Review 9.  Systemic therapy of brain metastases.

Authors:  Harry C Brastianos; Daniel P Cahill; Priscilla K Brastianos
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

Review 10.  Strategies for overcoming the blood-brain barrier for the treatment of brain metastases.

Authors:  Jethro Hu; Santosh Kesari
Journal:  CNS Oncol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.